ARCALYST(TM), First And Only FDA-approved Treatment For Cryopyrin-Associated Periodic Syndromes (CAPS), Now Available In The United States
Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced ARCALYST? (rilonacept) Injection for Subcutaneous Use is now available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. Regeneron was granted marketing approval for ARCALYST by the U.S.
More: continued here